Consistently, the Tyr75Ala mutation in tumor cells with low CD96 expression promotes chemotherapy efficiency in vivo rather than the Gln46Ala mutation, which was assessed by tumor size and 18F‐flourodeoxyglucose (18F‐FDG) Positron Emission Tomography/Computed Tomography (PET‐CT) (Figure 7G and Figure S6H,I, Supporting Information). The gene discussed is CD96; the disease is neoplasm.